SEARCH

SEARCH BY CITATION

References

  • 1
    Chobanian AV, Bakris GL, Black HR,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 2
    Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC task force on the management of arterial hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;25:17511762.
  • 3
    National Collaborating Centre for Chronic Conditions. Hypertension: Management in Adults in Primary Care: Pharmacological Update. London: Royal College of Physicians; 2006.
  • 4
    Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation. 2006;113:12131225.
  • 5
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:16841689.
  • 6
    Lindholm LH, Carlberg B, Samuelsson O. Should b-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:15451553.
  • 7
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 8
    Carella AM, Antonucci G, Conte M, et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev. 2010;6:215221.
  • 9
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:25342544.
  • 10
    Messerli FH, Grossman F, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. J Am Med Assoc. 1998;279:19031907.
  • 11
    Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174:17371742.
  • 12
    Wang KL, Cheng HM, Sung Sh, et al. Wave reflection and arterial stiffness in the prediction of 15-year all cause and cardiovascular mortalities: a community-based study. Hypertension. 2010;55:799805.
  • 13
    Vlachopoulos C, Aznaouridis K, O’Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:18651871.
  • 14
    McEniery CM, Yasmin, Maki-Petaja KM, et al. The impact of cardiovascular risk factors on aortic stiffness and wave reflections depends on age: the Anglo-Cardiff Collaborative Trial (ACCT III). Hypertension. 2010;56:591597.
  • 15
    Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003;34:12031206.
  • 16
    Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:25882605.
  • 17
    Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:22272236.
  • 18
    Kveiborg B, Christiansen B, Major-Petersen A, et al. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs. 2006;6:209217.
  • 19
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial–blood pressure lowering arm (ASCOT–BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895906.
  • 20
    Mahmud A, Feely J. β-Blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hyperten. 2008;21:663667.
  • 21
    Asmar RG, London GM, O’Rourke M, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension. 2001;38:922926.
  • 22
    Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525:263270.
  • 23
    Ting CT, Brin KP, Lin SJ, et al. Arterial hemodynamics in human hypertension. J Clin Invest. 1986;78:14621471.
  • 24
    Xiaozhen H, Yun Z, Mei Z, et al. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press. 2010;19:4047.
  • 25
    Kelly RP, Daley J, Avolio A, et al. Arterial dilatation and reduced wave reflection: benefit of dilevalol in hypertension. Hypertension. 1989;14:1421.
  • 26
    Tzemos N, Lim PO, MacDonald TM. Nobivolol reverses endothelial dysfunction in essential hypertension: a randomised, double blind, crossover study. Circulation. 2001;104:511514.
  • 27
    Gullu H, Erdogan D, Caliskan M, et al. Different effects of atenolol and nebivolol on coronary flow reserve. Heart. 2006;92:16901691.
  • 28
    Polónia J, Barbosa L, Silva JA, et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit. 2010;15:235239.
  • 29
    Agabiti-Rosei E, Mancia G, O’Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154160.
  • 30
    Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension. 2009;54:375383.
  • 31
    Nichols WW, O’Rourke MF. McDonald’s Blood Flow in Arteries, 5th ed. London, UK: Arnold; 2005.
  • 32
    Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25:731741.
  • 33
    Jonsson G, Abdelnoor M, Seljeflot I, et al. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J CardiovascPharmacol. 2007;49:2732.
  • 34
    Goldhammer E, Maor I, Shnitzer S, et al. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. J Cardiovasc Med (Hagerstown). 2007;8:453456.
  • 35
    Afonso RA, Patarrao RS, Macedo MP, et al. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006;19:419425.
  • 36
    Weber MA, Sica DA, Tarka EA, et al. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006;98(suppl 7):32L38L.
  • 37
    Zeneca Pharmaceuticals. Tenormin [package insert]. Wilmington, DE: Zeneca Pharmaceuticals; 1997.
  • 38
    GlaxoSmithKline. Coreg CR [package insert]. Research Triangle Park, NC; GlaxoSmithKline; October 2006.
  • 39
    Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011; 57(6):11221128.
  • 40
    Montgomery SM, Berney LR, Blane D. Prepubertal stature and blood pressure in early old age. Arch Dis Child. 2000;82:358363.
  • 41
    Langenberg C, Hardy R, Kuh D, et al. Influence of height, leg and trunk length on pulse pressure, systolic and diastolic blood pressure. J Hypertens. 2003;21:537543.
  • 42
    Smulyan H, Marchais SJ, Pannier B, et al. Influence of body height on pulsatile arterial hemodynamic data. J Am CollCardiol. 1998;31:11031109.